CHRS · Insider Trading
Coherus Oncology, Inc. Common Stock
Every open-market purchase and sale reported by CHRS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-09 | Rita A Karachun | Director | A | +30,000 | — |
| 2026-06-09 | Michael Lee Ryan | Director | A | +30,000 | — |
| 2026-06-09 | Lee Nisley Newcomer | Director | A | +30,000 | — |
| 2026-06-09 | Jill O'Donnell-Tormey | Director | A | +30,000 | — |
| 2026-06-09 | Charles W. Newton | Director | A | +30,000 | — |
| 2026-06-09 | Mats Wahlstrom | Director | A | +30,000 | — |
| 2026-06-09 | Ali J. Satvat | Director | A | +30,000 | — |
| 2026-06-02 | Bryan J McMichael | Chief Financial Officer | MIXED | — | — |
| 2026-06-02 | Dennis M Lanfear | President & CEO | MIXED | −500,000 deriv. | — |
| 2026-01-26 | Bryan J McMichael | Chief Financial Officer | A | +112,500 | — |
| 2026-01-26 | Dennis M Lanfear | President & CEO | A | +375,000 | — |
| 2026-01-22 | Bryan J McMichael | Chief Financial Officer | F | −1,715 | −$2.66K |
| 2026-01-22 | Dennis M Lanfear | President & CEO | F | −11,839 | −$18.35K |
| 2025-06-13 | Georgia Erbez | Director | A | +112,000 deriv. | — |
| 2025-06-13 | Michael Lee Ryan | Director | A | +112,000 deriv. | — |
| 2025-06-13 | Charles W. Newton | Director | A | +112,000 deriv. | — |
| 2025-06-13 | Rita A Karachun | Director | A | +112,000 deriv. | — |
| 2025-06-13 | Lee Nisley Newcomer | Director | A | +112,000 deriv. | — |
| 2025-06-13 | Ali J. Satvat | Director | A | +112,000 deriv. | — |
| 2025-06-13 | Mats Wahlstrom | Director | A | +112,000 deriv. | — |
| 2025-06-13 | Jill O'Donnell-Tormey | Director | A | +112,000 deriv. | — |
| 2025-05-28 | Mats Wahlstrom | Director | Sell | −99,988 | −$73.88K |
| 2025-05-09 | Dennis M Lanfear | President & CEO | A | +375,000 deriv. | — |
| 2025-05-09 | Bryan J McMichael | Chief Financial Officer | A | +200,000 deriv. | — |
| 2025-01-22 | Paul Reider | Chief Commercial Officer | F | −4,858 | −$6.75K |
| 2025-01-22 | Bryan J McMichael | Chief Financial Officer | F | −1,711 | −$2.38K |
| 2025-01-22 | Dennis M Lanfear | President & CEO | F | −11,810 | −$16.42K |
| 2025-01-14 | Dennis M Lanfear | President & CEO | A | +575,000 deriv. | — |
| 2025-01-10 | Bryan J McMichael | Chief Financial Officer | F | −1,711 | −$2.69K |
| 2025-01-07 | Dennis M Lanfear | President & CEO | F | −11,810 | −$19.60K |
| 2025-01-07 | Bryan J McMichael | Chief Financial Officer | A | +160,000 deriv. | — |
| 2025-01-07 | Paul Reider | Chief Commercial Officer | F | −2,277 | −$3.78K |
| 2024-12-17 | Paul Reider | Chief Commercial Officer | F | −2,073 | −$3.34K |
| 2024-08-09 | Bryan J McMichael | Chief Financial Officer | A | +75,000 deriv. | — |
| 2024-07-24 | Dennis M Lanfear | President & CEO | A | +196,500 deriv. | — |
| 2024-07-24 | Paul Reider | Chief Commercial Officer | A | +40,000 deriv. | — |
| 2024-06-05 | Jill O'Donnell-Tormey | Director | A | +112,000 deriv. | — |
| 2024-06-05 | Rita A Karachun | Director | A | +168,000 deriv. | — |
| 2024-06-05 | Michael Lee Ryan | Director | A | +112,000 deriv. | — |
| 2024-06-05 | Charles W. Newton | Director | A | +112,000 deriv. | — |
| 2024-06-05 | Mats Wahlstrom | Director | A | +112,000 deriv. | — |
| 2024-06-05 | Kimberly Jo Tzoumakas | Director | A | +112,000 deriv. | — |
| 2024-06-05 | Lee Nisley Newcomer | Director | A | +112,000 deriv. | — |
| 2024-06-05 | Georgia Erbez | Director | A | +114,000 deriv. | — |
| 2024-06-05 | Mark Stolper | Director | A | +112,000 deriv. | — |
| 2024-02-22 | Georgia Erbez | Director | A | +54,000 deriv. | — |
| 2024-02-15 | Mats Wahlstrom | Director | G | — | — |
| 2024-02-05 | Mats Wahlstrom | Director | M | +59,988 | +$100.00K |
| 2024-01-23 | Paul Reider | Chief Commercial Officer | F | −4,854 | −$11.84K |
| 2024-01-23 | Bryan J McMichael | See Remarks | F | −1,707 | −$4.17K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Dennis M Lanfear | President & CEO | 1,135,200 | $1.19M |
| Bryan J McMichael | Chief Financial Officer | 133,736 | $140.42K |
| Paul Reider | Chief Commercial Officer | 82,069 | $86.17K |
| Mats Wahlstrom | Director | 30,000 | $31.50K |
| Rita A Karachun | Director | 30,000 | $31.50K |
| Ali J. Satvat | Director | 30,000 | $31.50K |
| Lee Nisley Newcomer | Director | 30,000 | $31.50K |
| Charles W. Newton | Director | 30,000 | $31.50K |
| Jill O'Donnell-Tormey | Director | 30,000 | $31.50K |
| Michael Lee Ryan | Director | 30,000 | $31.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CHRS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.